Applied StemCell, or ASC, is a contract research, development, and manufacturing organization in support of novel therapeutics. Its trademarked TARGATT technology offers fast and precise gene editing of large DNA fragments, which in turn allows shorter manufacturing timelines, as well as genomic stability and safety.
QHP’s investment in the company reflects a history of healthcare and pharma investment. Spun off from IQVIA (formerly Quintiles Transnational) in 2010, the company has been involved in life science investments – specifically biopharmaceutical – since its inception in 2000.
“Applied StemCell fits with QHP’s investment focus of providing strategic capital and support to firms with established offerings that are positioned to scale to meet the needs of the industry,” said Matt Jenkins and Jeff Edwards, Partners at QHP Capital in yesterday’s press release. “We look forward to working with ASC as they expand their commercial organization and broaden their market presence.”